Targeting microglia: A new strategy for the treatment of Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and preclinical concepts without systematic methodology or primary human trial data
PubMed 42160848 · doi:10.1016/j.jneuroim.2026.578966
What was done
This narrative review synthesizes current preclinical and mechanistic literature on the role of microglia in Alzheimer's disease pathogenesis. It examines microglial activation states (such as disease-associated microglia), metabolic reprogramming, aging-related dysfunction, and key receptor pathways including TREM2, APOE, and neurotransmitter receptors. It also reviews experimental therapeutic approaches aimed at restoring homeostatic microglial function.
What was found
The abstract provides no quantitative data or numerical results. It descriptively summarizes the dual neuroprotective and neurotoxic roles of microglia, their influence on amyloid-beta clearance and tau propagation, and proposed therapeutic strategies such as pharmacological neuroinflammatory modulation, metabolic interventions, and cell transplantation.
Why it matters
Targeting microglial dysfunction and neuroinflammation represents an important potential therapeutic avenue for Alzheimer's disease beyond direct amyloid clearance. It highlights specific molecular targets like TREM2 and microglial metabolic pathways for drug development.
Limits
The paper is a narrative review with no original clinical or experimental data reported in the abstract. Significant clinical translation barriers exist, including microglial plasticity, determining the temporal window of intervention, and a lack of established efficacy in human clinical trials.
Cited by
- supports Microglial cells clear beta-amyloid from the brain.